nasdaq:abus
|
254364
|
Apr 21st, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
91.00
|
Open
|
|
Apr 20th, 2024 10:43PM
|
Apr 20th, 2024 10:43PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 20th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
91.00
|
Open
|
|
Apr 19th, 2024 10:35PM
|
Apr 20th, 2024 04:28PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 19th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
91.00
|
Open
|
|
Apr 18th, 2024 10:42PM
|
Apr 18th, 2024 10:42PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 18th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
91.00
|
Open
|
|
Apr 17th, 2024 10:39PM
|
Apr 18th, 2024 05:48PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 17th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
91.00
|
Open
|
|
Apr 16th, 2024 10:33PM
|
Apr 17th, 2024 02:11PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 16th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
91.00
|
Open
|
|
Apr 15th, 2024 10:32PM
|
Apr 16th, 2024 10:28AM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 15th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
92.00
|
Open
|
|
Apr 14th, 2024 10:34PM
|
Apr 15th, 2024 04:08PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 14th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
92.00
|
Open
|
|
Apr 13th, 2024 10:29PM
|
Apr 13th, 2024 10:29PM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 13th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
92.00
|
Open
|
|
Apr 12th, 2024 10:19PM
|
Apr 13th, 2024 10:56AM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:abus
|
254364
|
Apr 12th, 2024 12:00AM
|
Arbutus Biopharma Corporation
|
6.3K
|
92.00
|
Open
|
|
Apr 11th, 2024 10:22PM
|
Apr 12th, 2024 07:51AM
|
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
|
Open
|
|
Open
|
701 Veterans Circle
|
Warminster
|
Pennsylvania
|
US
|
18974
|
|
Arbutus Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|